Improving health evaluations to capture wider value of therapeutics and incentivise innovation
Bibliographic Data
| ID | 22071180 |
|---|---|
| Authors | Mei Sum Chan, Jack C Kowalik (Pfizer (United Kingdom)), Tom Ashfield (0000-0001-8082-3821, Pfizer (United Kingdom)), Jonathan Pearson-Stuttard (0000-0003-2175-9975, Imperial College London, corresponding author) |
| Year | 2023 |
| Volume | 11 |
| Pages | 1119652-1119652 |
| Publication date | 2023-03-31 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2023.1119652 |
| PMID | 37064703 |
| OpenAlex | W4362467148 |
| Language | EN |
| Citations received | 1 |
| References cited | 11 |
elements of value, insurance value, antimicrobial resistance, pandemics, value assessment Prevention is better than cure-but how to value prevention and incentivise investment
Business · Data science · Antibiotic Use and Resistance · Computer Science · Health Systems, Economic Evaluations, Quality of Life · Healthcare cost, quality, practices · Medicine
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |